Welcome to our dedicated page for Outlook Therapeutics news (Ticker: OTLKW), a resource for investors and traders seeking the latest updates and insights on Outlook Therapeutics stock.
News for OTLKW reflects developments at Outlook Therapeutics, Inc., a biopharmaceutical company concentrated on ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma), an ophthalmic formulation of bevacizumab for retinal diseases such as wet age-related macular degeneration (wet AMD). Company news frequently reiterates this focus on enhancing or optimizing the standard of care for bevacizumab in retina indications.
Readers can expect coverage of regulatory milestones, including interactions with the U.S. Food and Drug Administration (FDA) around the Biologics License Application (BLA) for ONS-5010. Recent announcements have described complete response letters, Type A meetings, BLA resubmissions, and FDA acknowledgments of resubmissions as complete, along with associated Prescription Drug User Fee Act (PDUFA) goal dates. These updates provide context on the regulatory pathway for the investigational product in the United States.
The OTLKW news feed also includes information on European commercialization of LYTENAVA™ (bevacizumab gamma), where Outlook Therapeutics reports that the product has received Marketing Authorization from the European Commission and the UK MHRA for the treatment of wet AMD and has been launched commercially in Germany and the UK. News items describe initial sales into distribution channels, early prescribing trends, and efforts to expand into additional European markets, subject to pricing and reimbursement approvals in certain Member States.
Additional news topics include corporate and investor events, such as participation in healthcare conferences, presentations at ophthalmology-focused meetings, and the appointment of senior executives in corporate strategy and business development. Disclosures on stock option grants to new employees as employment inducement awards may also appear. For investors and observers following OTLKW, this news page offers a centralized view of Outlook Therapeutics’ reported clinical, regulatory, commercial, and corporate developments related to its ophthalmic bevacizumab program.
Outlook Therapeutics, a clinical-stage biopharmaceutical company, announced that its CEO, Lawrence A. Kenyon, will engage in a fireside chat at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The event will include opportunities for virtual one-on-one meetings with investors. Outlook Therapeutics is focused on developing ONS-5010/LYTENAVA (bevacizumab-vikg), the first FDA-approved ophthalmic formulation for retinal indications including wet AMD, DME, and BRVO. The webcast of the chat will be available on demand starting March 9, 2021.
Outlook Therapeutics (Nasdaq: OTLK) announced that its CEO, Lawrence A. Kenyon, will participate in a virtual panel on February 19, 2021, hosted by Cantor Fitzgerald. The panel, titled “Eyeing Key Events and Programs in the Ophthalmology Space in 2021,” aims to discuss market opportunities and upcoming milestones in the ophthalmology sector. Outlook Therapeutics focuses on developing ONS-5010 (bevacizumab-vikg), potentially the first FDA-approved ophthalmic formulation for retinal diseases like wet AMD.
Outlook Therapeutics reported promising developments in its ophthalmic formulation, ONS-5010 / LYTENAVA™, targeting wet age-related macular degeneration (AMD). The Phase 3 study (NORSE TWO) is set to deliver safety and efficacy data in Q3 2021, while the open-label study (NORSE THREE) aims to report findings in Q2 2021. Recent funding of $42.6 million bolsters the company's financial position, enabling progress toward a Biologics License Application (BLA) submission planned for late 2021. The company recorded a reduced net loss of $14.5 million for Q1 FY2021, reflecting improved financial health.
Outlook Therapeutics announced the completion of the final patient visit for the NORSE THREE open-label safety study of ONS-5010/LYTENAVA™ (bevacizumab-vikg), a treatment for retinal diseases. The study, which enrolled 197 subjects over four weeks, is crucial for the planned Biologics License Application (BLA) submission to the FDA in Q4 2021. With two of three necessary clinical trials completed, Outlook anticipates significant market adoption of ONS-5010 if approved, and has begun commercial launch preparations. The company is also moving forward with agreements for additional trials under Special Protocol Assessments.
Outlook Therapeutics has raised aggregate gross proceeds of $41.6 million through a successful public offering and a concurrent private placement. The funding is aimed at supporting the Biologics License Application (BLA) filing for ONS-5010, an ophthalmic formulation of bevacizumab, intended for treating wet AMD and other retinal diseases. The company anticipates filing the BLA by the end of 2021, bolstered by completed clinical trials and a robust commercialization strategy.
Outlook Therapeutics (Nasdaq: OTLK) announced an increase in its public offering to 35 million shares of common stock at $1.00 per share, expected to close around February 2, 2021. The offering aims to raise approximately $35 million for working capital and support its ONS-5010 development program. Additionally, GMS Ventures, an affiliate of its largest shareholder, plans to purchase up to $8.36 million of shares. A concurrent private placement will sell 3 million shares to Syntone Ventures for about $3 million.
Outlook Therapeutics (Nasdaq: OTLK) has announced an underwriting agreement with H.C. Wainwright & Co. to offer 10 million shares of common stock at $1.00 each, aiming to raise approximately $10 million in gross proceeds. The offering will close around February 2, 2021, pending customary conditions. The company plans to use the proceeds for general corporate purposes and to support its ONS-5010 development program. The underwriter has the option to purchase an additional 1.5 million shares. This offering is conducted under an effective SEC registration statement.
On January 12, 2021, Outlook Therapeutics (OTLK) announced a podcast featuring Dr. Firas Rahhal discussing the need for an FDA-approved ophthalmic formulation of bevacizumab, specifically ONS-5010, for retinal diseases. COO Terry Dagnon and CCO Jeff Evanson elaborated on the clinical development strategy for ONS-5010, which is currently in Phase 3 trials. The drug aims to meet a market demand in the $13 billion anti-VEGF therapy market, providing a safe, cGMP-produced alternative to off-label bevacizumab. The BLA filing with the FDA for wet AMD is anticipated in the second half of 2021.
Outlook Therapeutics, a late clinical-stage biopharmaceutical company, has announced that Lawrence A. Kenyon, its President, CEO, and CFO, will present at the H.C. Wainwright BioConnect 2021 Virtual Conference from January 11-14, 2021. During this event, Kenyon will discuss the development of ONS-5010/LYTENAVA™, the first FDA-approved ophthalmic formulation of bevacizumab-vikg for retinal diseases. A video webcast of the presentation will be available on-demand starting January 11, 2021, at 6:00 AM ET on their website.
Outlook Therapeutics announced pivotal updates regarding ONS-5010 / LYTENAVA™ and financial results for the fiscal year ending September 30, 2020. The company reported a net loss of $48.9 million, or $0.67 per share, an increase from $36.0 million in the previous year. All planned clinical trials for ONS-5010 are fully enrolled or completed, with pivotal data from the Phase 3 trial expected in mid-2021, followed by a BLA submission. Outlook anticipates engaging with regulatory authorities in Europe and plans further registration trials for diabetic macular edema and branch retinal vein occlusion.